Brief: Geneuro Receives Orphan Drug Designation From The Us FDA For Gnbac1 In Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
22/02/2018 17:31
Geneuro Sa GNRO.PA :
* GENEURO RECEIVES ORPHAN DRUG DESIGNATION FROM THE US FDA
FOR
GNBAC1 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
(CIDP)
* FORTHCOMING DISCUSSIONS EXPECTED WITH FDA FOR DESIGN OF A
PROOF-OF-CONCEPT PHASE 2 CLINICAL STUDY
Source text for Eikon: ID:nBw5r1hMma
Further company coverage: GNRO.PA
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement